---
layout: post
title: "Clinical Pharmacology Considerations for Peptide Drug Products; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:56:46 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-19456
original_published: 2023-09-11 00:00:00 +0000
significance: 8.00
---

# Clinical Pharmacology Considerations for Peptide Drug Products; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** September 11, 2023 00:00 UTC
**Document Number:** 2023-19456

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Clinical Pharmacology Considerations for Peptide Drug Products." This guidance describes FDA's recommendations regarding clinical pharmacology considerations for peptide drug product development programs, including hepatic impairment, drug-drug interactions (DDIs), assessing QTc prolongation risk, and immunogenicity risk and impact on the pharmacokinetics (PK), safety, and efficacy assessment. The intent of this draft guidance, when finalized, is to assist industry in the conduct of these development programs.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/09/11/2023-19456/clinical-pharmacology-considerations-for-peptide-drug-products-draft-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2023-19456

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
